Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection

被引:60
作者
Wagner, R
Teeuwsen, VJP
Deml, L
Notka, F
Haaksma, AGM
Jhagjhoorsingh, SS
Niphuis, H
Wolf, H
Heeney, JL
机构
[1] Biomed Primate Res Ctr, Dept Virol, NL-2288 GJ Rijswijk, Netherlands
[2] Univ Regensburg, Inst Med Mikrobiol & Hyg, D-8400 Regensburg, Germany
关键词
D O I
10.1006/viro.1998.9104
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
HIV Pr55(gag) has in the absence of other viral components the capacity to self assemble in budding noninfectious virus-like particles (VLP). The immunological spectrum of the HIV-1@ gag-derived VLP was expanded either by stable anchoring of chimeric modified gp120 on the surface of the VLP (type 1) or by replacing sequences of the pr55(gag) precursor by the V3 loop and a linear portion of the CD4 binding domain (type 2). This noninfectious antigen delivery system was evaluated for immunogenicity and efficacy in rhesus macaques without adjuvants. Intramuscular immunization with both types of VLP induced high titers of gag-specific antibodies ranging from 1/8000 to 1/510,000 for type 1 VLP and from 1/4000 to 1/16,000 for type 2 VLP. Only animals immunized with type 1 VLP developed substantial endpoint titers of env-specific antibodies (1/2000-1/32,000) with a neutralizing capacity at serum dilutions of 1/32-1/128. Gag- and env-specific cytotoxic T lymphocyte (CTL) activity was induced by both types of VLP at: similar levels. Four weeks after the last immunization animals were challenged intravenously with 20 MID50 of the cell free homologous envelops simian/HIV-1(IIIB) chimeric challenge stock. Despite HIV-1-specific neutralizing and CTL responses, all vaccinated animals became infected. (C) 1998 Academic Press.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 46 条
[1]   HIV SUPPRESSION BY INTERLEUKIN-16 [J].
BAIER, M ;
WERNER, A ;
BANNERT, N ;
METZNER, K ;
KURTH, R .
NATURE, 1995, 378 (6557) :563-563
[2]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[3]   VIRUS-SPECIFIC CD8+ CYTOTOXIC T-LYMPHOCYTE ACTIVITY ASSOCIATED WITH CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
BORROW, P ;
LEWICKI, H ;
HAHN, BH ;
SHAW, GM ;
OLDSTONE, MBA .
JOURNAL OF VIROLOGY, 1994, 68 (09) :6103-6110
[4]  
BOURGAULT I, 1994, J IMMUNOL, V152, P2530
[5]   CYTOTOXIC T-CELL RESPONSE AND AIDS-FREE SURVIVAL IN SIMIAN IMMUNODEFICIENCY VIRUS-INFECTED MACAQUES [J].
BOURGAULT, I ;
VILLEFROY, P ;
BEYER, C ;
AUBERTIN, AM ;
LEVY, JP ;
VENET, A .
AIDS, 1993, 7 :S73-S79
[6]   HIV-1 ENVELOPE-ELICITED NEUTRALIZING ANTIBODY-TITERS CORRELATE WITH PROTECTION AND VIRUS LOAD IN CHIMPANZEES [J].
BRUCK, C ;
THIRIART, C ;
FABRY, L ;
FRANCOTTE, M ;
PALA, P ;
VANOPSTAL, O ;
CULP, J ;
ROSENBERG, M ;
DEWILDE, M ;
HEIDT, P ;
HEENEY, J .
VACCINE, 1994, 12 (12) :1141-1148
[7]   QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE [J].
CARMICHAEL, A ;
JIN, X ;
SISSONS, P ;
BORYSIEWICZ, L .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) :249-256
[8]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[9]   Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55(gag) virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain [J].
Deml, L ;
Kratochwil, G ;
Osterrieder, N ;
Knuchel, R ;
Wolf, H ;
Wagner, R .
VIROLOGY, 1997, 235 (01) :10-25
[10]   Recombinant human immunodeficiency Pr55(gag) virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies [J].
Deml, L ;
Schirmbeck, R ;
Reimann, J ;
Wolf, H ;
Wagner, R .
VIROLOGY, 1997, 235 (01) :26-39